When was Abcellera Biologics founded?

Abcellera Biologics was founded in 2012 and raised its 1st funding round 6 years after it was founded.

Where is Abcellera Biologics located?

Abcellera Biologics is headquartered in Vancouver, Canada.

Who is the current CEO of Abcellera Biologics?

Carl Hansen of Abcellera Biologics.

How many employees does Abcellera Biologics have?

As of Aug 31, 2026, the latest employee count at Abcellera Biologics is 588.

Is Abcellera Biologics a funded company?

Abcellera Biologics is a funded company, having raised a total of $115M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 07, 2018.

When was the latest funding round of Abcellera Biologics?

Abcellera Biologics' latest funding was a $***** Post IPO round on Jun 10, 2021, with participation from 0 investor.

What is the annual revenue of Abcellera Biologics?

Annual revenue of Abcellera Biologics is between $50M and $100M as on Dec 31, 2025

Where does Abcellera Biologics rank among its competitors?

Abcellera Biologics ranks 5th amongst 734 active competitors, of which 253 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Biogen, which secured an undisclosed amount in Feb, 2024.

Who are the top competitors of Abcellera Biologics?

Abcellera Biologics' top competitors include BeiGene, Biogen and argenx. Among them, Biogen secured the most recent funding round in February, 2024.

Abcellera Biologics - 2026 Company Profile, Team, Funding, Competitors & Financials

Abcellera Biologics is a public company based in Vancouver (Canada), founded in 2012. It operates as an AI-enabled platform for antibodies discovery. Abcellera Biologics has raised $115M in funding from DCVC and Orbimed. The company has 734 active competitors, including 253 funded and 179 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.

Company Details

AI-enabled platform for antibodies discovery. The company has developed Celium which is an antibody visualization software and suite of proprietary microfluidic single-cell assays used for antibody screening. The company uses its proprietary repertoire sequencing technologies with functional data from single B cells to annotate immune repertoires. It has also developed its proprietary humanized mouse platform for the development of humanized antibodies.

Website: www.abcellera.com/
Social
Email ID: *****@abcellera.com
Phone Number: +1 **********

Key Metrics

Founded Year

2012

Location

Vancouver, Canada

Stage

Public

Total Funding

$115M in 5 rounds

Latest Funding Round

Post IPO, Jun 10, 2021, $*****

Investors

DCVC & 17 more

Ranked

5^th among 734 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

588 as on Aug 31, 2026

Investment & Acquisitions

Abdera Therapeutics & 4 more

Similar Companies

BeiGene & 898 more

Exit Details

Public

View Abcellera Biologics' full profile

Abcellera Biologics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Abcellera Biologics Inc. CIN: 1703057 , United States, Active		$50M - $100M (As on Dec 31, 2025)	-	-

Abcellera Biologics got listed on Dec 11, 2020.

Click here to take a look at Abcellera Biologics's IPO in detail

Abcellera Biologics has raised a total funding of $115M over 5 rounds. Its first funding round was on Mar 07, 2018. Abcellera Biologics has 16 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Abcellera Biologics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 10, 2021	4780176	Post IPO	5448362	7578450	3381039	3451864
May 2020	3650000	Grant (prize money)	9550516	9275707	8377442	Canadian Space Agency
Mar 23, 2020	1858606	Series B	6220171	5313128	Orbimed & 1 more	Viking Global Investors & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Abcellera Biologics's funding rounds and investors

Abcellera Biologics' employee count trend

Abcellera Biologics has 588 employees as of Aug 26. Here is Abcellera Biologics's employee count trend over the years:

Employee count trend for Abcellera Biologics

Uncover Abcellera Biologics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Abcellera Biologics include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Abcellera Biologics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
5th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	HTIF, Benson Family Private Equity & 16 others	71/100
6th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
7th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
9th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
10th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Abcellera Biologics's competitors? Click here to see the top ones

Abcellera Biologics has made 3 investments in companies including Abdera Therapeutics and Abdera Therapeutics. Abcellera Biologics has also acquired 2 companies including Tetra Genetics Research and Trianni.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 20, 2023	Investments	Abdera Therapeutics	2020	Vancouver (Canada)
Sep 13, 2021	Acquisition	Tetra Genetics Research	2004	Arlington (United States)
2021	Investments	Abdera Therapeutics	2020	Vancouver (Canada)

Want to know more about where corporates are investing? Sign up today!

Here is the latest report on Abcellera Biologics's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Abcellera Biologics

Media has covered Abcellera Biologics for a total of 24 events in the last 1 year, 12 of them have been about company updates and 3 about partnerships.